TriangleNCT00217425 · OUTCOME
12-Month Progression-Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- probability
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Assessed every 3 months the first 2 years from study entry and every 6 months 3-5 years from study entry.
What was measured
12-month progression-free survival is defined as the probability of patients remaining alive and progression-free at 12 months from study entry.
Analysis population: Eligible and treated patients
Groups in this outcome
Treatment (A-CHOP Followed by MA)
Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 \[max. 2 mg\]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.
| Group | Source count |
|---|---|
| Treatment (A-CHOP Followed by MA) | 39 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (A-CHOP Followed by MA) | 0.44 | Not reported | .31 | .63 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- .31
- upper Limit
- .63
- value
- 0.44
- denoms
- counts
- group Id
- OG000
- value
- 39
- units
- Participants
- description
- 12-month progression-free survival is defined as the probability of patients remaining alive and progression-free at 12 months from study entry.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 \[max. 2 mg\]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.
- id
- OG000
- title
- Treatment (A-CHOP Followed by MA)
- param Type
- NUMBER
- population Description
- Eligible and treated patients
- reporting Status
- POSTED
- time Frame
- Assessed every 3 months the first 2 years from study entry and every 6 months 3-5 years from study entry.
- title
- 12-Month Progression-Free Survival (PFS)
- type
- PRIMARY
- unit Of Measure
- probability
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice